End-stage kidney disease and rationing of kidney replacement therapy in the free state province, South Africa: a retrospective study

被引:4
|
作者
Molaoa, Thabang T. [1 ]
Bisiwe, Feziwe B. [1 ]
Ndlovu, Kwazi C. Z. [2 ,3 ]
机构
[1] Univ Free State, Div Nephrol, Dept Internal Med, Bloemfontein, South Africa
[2] Univ Cape Town, Div Nephrol & Hypertens, Cape Town, South Africa
[3] Univ Cape Town, Kidney & Hypertens Res Unit, Cape Town, South Africa
关键词
Incidence rate; End-stage kidney disease; Kidney replacement therapy; Dialysis access; South Africa; SUB-SAHARAN-AFRICA; RENAL-DISEASE; PERITONEAL-DIALYSIS; HEALTH-CARE; TRANSPLANTATION; PREVENTION; PREVALENCE; OUTCOMES; OLDER; HIV;
D O I
10.1186/s12882-021-02387-x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background End-stage kidney disease (ESKD) and the required kidney replacement therapy (KRT) are significant public health challenges for low-and-middle-income countries. The South African government adopted a KRT rationing policy to balance the growing need for KRT and scarce resources. We aimed to describe the epidemiology and KRT access in patients with ESKD referred to the main public sector hospital in the Free State Province, South Africa. Methods A retrospective study of adult patients with ESKD admitted to Universitas Academic Hospital for KRT, was conducted between 1 January 2016 and 31 December 2018. A review of the KRT committee decisions to offer or deny KRT based on the KRT rationing policy of the Free State was undertaken. Demographic information, KRT committee outcomes, laboratory test results, and clinical details were collected from assessment tools, KRT committee meeting diaries, and electronic hospital records. Results Of 363 patients with ESKD referred for KRT access, 96 with incomplete records were excluded and 267 were included in the analysis. Median patient age was 40 (interquartile range, 33-49) years, and male patients accounted for 56.2 % (150/267, p = 0.004) of the cohort. The average annual ESKD incidence was 49.9 (95 % confidence interval [CI], 35.8-64.0) per-million-population. The most prevalent comorbidities were hypertension (42.3 %; 113/267), human immunodeficiency virus (HIV) (28.5 %; 76/267), and diabetes mellitus (19.1 %; 51/267). The KRT access rate was 30.7 % (82/267), with annual KRT incidence rates of 8.05 (95 % CI, 4.98-11.1), 11.5 (95 % CI, 7.83-15.1), and 14.1 (95 % CI, 10.3-18.0) per-million-population in 2016, 2017, and 2018, respectively. Advanced organ dysfunction was the commonest reason recorded for KRT access denial (58.9 %; 109/185). Age (odds ratio [OR], 1.04; 95 % CI, 1.00-1.07; p = 0.024) and diabetes (OR, 5.04; CI, 1.69-15.03; p = 0.004) were independent predictors for exclusion from KRT, while hypertension (OR, 1.80; 1.06-3.04; p = 0.029) independently predicted advanced organ dysfunction resulting in KRT exclusion. Conclusions Non-communicable and communicable diseases, including hypertension, diabetes, and HIV, contributed to ESKD, highlighting the need for improved early prevention strategies to address a growing incidence rate. Two-thirds of ESKD patients were unable to access KRT, with age, diabetes mellitus, and advanced organ dysfunction being significant factors adversely affecting KRT access.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Palliative care in end-stage kidney disease
    Fassett, Robert G.
    Robertson, Iain K.
    Mace, Rose
    Youl, Loren
    Challenor, Sarah
    Bull, Rosalind
    NEPHROLOGY, 2011, 16 (01) : 4 - 12
  • [42] Anemia and Incident End-Stage Kidney Disease
    Saraf, Santosh L.
    Hsu, Jesse Y.
    Ricardo, Ana C.
    Mehta, Rupal
    Chen, Jing
    Chen, Teresa K.
    Fischer, Michael J.
    Hamm, Lee
    Sondheimer, James
    Weir, Matthew R.
    Zhang, Xiaoming
    Wolf, Myles
    Lash, James P.
    KIDNEY360, 2020, 1 (07): : 623 - 630
  • [43] Kidney Function and Long-Term Risk of End-Stage Kidney Disease and Mortality in a Multiethnic Population
    Ling, Suping
    Xu, Gang
    Zaccardi, Francesco
    Khunti, Kamlesh
    Brunskill, Nigel J.
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (09): : 1761 - 1771
  • [44] Cancer Screening in End-Stage Kidney Disease
    Shirazian, Shayan
    Starakiewicz, Piotr
    Latcha, Sheron
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (05) : 502 - +
  • [45] The Safety and Effectiveness of Apixaban in Patients with End-Stage Kidney Disease on Dialysis: A Retrospective Observational Study
    El Nekidy, Wasim
    Abidi, Emna
    Nabil, Said
    Kendakji, Saba
    Ali, Moatasem
    Aburuz, Salahdein
    Atallah, Bassam
    Hijazi, Fadi
    Mallat, Jihad
    Akour, Amal
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
  • [46] Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study
    Rivedal, Mariell
    Haaskjold, Yngvar Lunde
    Eikrem, Oystein
    Bjorneklett, Rune
    Marti, Hans Peter
    Knoop, Thomas
    BMC NEPHROLOGY, 2024, 25 (01) : 42
  • [47] Appropriateness of Antiplatelet Therapy and Proton Pump Inhibitor Prescribing in End-Stage Kidney Disease: A Retrospective Quality Investigation Study
    Che, Michael
    Ahmed, Sumaiya
    Chan, Ryan
    Akbari, Ayub
    Zimmerman, Deborah
    CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE, 2025, 12
  • [48] A five-year longitudinal study of the relation between end-stage kidney disease as the outcomes
    Li, Hsiu-Lan
    Tai, Pei-Hui
    Hwang, Yi-Ting
    Lin, Shih-Wei
    BMC NEPHROLOGY, 2020, 21 (01)
  • [49] Progression to end-stage kidney disease in Japanese children with chronic kidney disease: results of a nationwide prospective cohort study
    Ishikura, Kenji
    Uemura, Osamu
    Hamasaki, Yuko
    Ito, Shuichi
    Wada, Naohiro
    Hattori, Motoshi
    Ohashi, Yasuo
    Tanaka, Ryojiro
    Nakanishi, Koichi
    Kaneko, Tetsuji
    Honda, Masataka
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (04) : 878 - 884
  • [50] Validation of the kidney failure risk equation for end-stage kidney disease in Southeast Asia
    Wang, Yeli
    Nguyen, Francis Ngoc Hoang Long
    Allen, John C.
    Lew, Jasmine Quan Lan
    Tan, Ngiap Chuan
    Jafar, Tazeen H.
    BMC NEPHROLOGY, 2019, 20 (01)